ࡱ> ikh[ 8bjbj~~ 7bbb}0Nt t 8<l<!5...4444444$794..444R44.|j/ Em.440!5/Z]:]:$j/j/]:\30."Ph|...44y...!5]:.........t B : Edward VIA College of Osteopathic Medicine PARENT PERMISSION FORM Title of Activity Investigator(s) List names, positions, divisions, telephone numbers and email addresses of all individuals involved in the project. 24-Hour Emergency Telephone Number Include Name and Position; this is only for studies involving more than minimal risk. Investigators Statement We are asking your child to be in a research study. The purpose of this consent form is to give you the information you will need to help you decide whether to allow your child to be in the study or not. Please read the form carefully. You may ask questions about the purpose of the research, the possible risks and benefits, and anything else about the research or this form that is not clear. When we have answered all your questions, you can decide if you want your child to participate in the study or not. We will give you a copy of this form for your records. Additionally, your child will be given a form called an Assent Form that will also explain the purpose of the study and what it entails. The Assent Form will be given to your child thereby allowing them to choose if they wish to take part in the study or not. The purpose of this parent permission form is to help explain the purposes of the study and if you are willing to allow your child to participate in this study. Purpose of this Research/Project Subjects should be informed in clear, concise language about the nature of the study and the purpose for conducting the research. The total number of subjects involved and a brief description of the subject pool (age range, health status, etc.) should be given. Procedures Describe the procedures involved. Use separate paragraphs to describe each procedure. Include the commitment of time for each, the total amount of time involved, and how long the study will last. Include where the research will take place. As appropriate, specify size of samples to be taken and names and doses of substances to be given. Describe ownership, use, disposal and documentation (identification) procedures for any specimens or samples that will be taken. Describe questionnaires, surveys and interviews and describe or provide examples of the most personal and sensitive questions you will ask. Include the use of medical, academic or other records, photographs, audio or visual recordings. Add a study flow chart or table, if available. At the end of this section, the subjects must have a clear understanding of what will be expected of them. Remember, all language should be no higher than an eighth-grade reading level. Risks, Stress or Discomfort Include information on the psycho-social and physical risks, including side effects, stress, discomforts, breach of confidentiality or the invasion of privacy that might result from each procedure. Safeguards that are to be employed to reduce or minimize the risks must be described. Do not state that there are no risks or that risks should be minimal. If appropriate, state how side effects will be handled and whom the subject should contact in the event of a study-related injury, illness or distress. If investigational drugs are used, state that you will provide subjects with any information developed during the study that might affect their willingness to participate. If you will make recordings of subjects, and you will be keeping the recordings indefinitely, share them with other researchers or use them in presentations or publications, explain that subjects will be given an opportunity to review the recordings and delete any portions. Alternatives to Taking Part in this Study For studies involving interventions (educational, social, medical or other) include descriptions of alternative procedures or standard care that are available if a subject chooses not to be in the study. Benefits of the Study Describe the tangible or intangible benefits, if any, to the subjects who participate. State if subjects will not benefit from being in the study. If applicable, state the larger societal benefits for conducting the research. An analysis of the risks to benefits must clearly be on the benefits side. A statement must be included to the effect that: no promise or guarantee of benefits has been made to encourage you to participate. At the option of the investigator, subjects may be informed that they may contact the researcher at a later time for a summary of the research results. If subjects are children, the parent / guardian must make the request. Extent of Anonymity and Confidentiality The extent to which subjects will be identifiable must be explained. If anonymity is promised (individuals cannot be identified), you need to explain how that will be accomplished. If confidentiality is promised (individuals can be identified, but the researchers promise not to divulge that information), you must explain how that will be accomplished (e.g., computer password protected or by locked file cabinets) and state the date when the link will be broken. If information from an individuals medical charts will be reviewed, this must be stated. In some situations, it may be necessary for an investigator to break confidentiality. If child / elder abuse is known or strongly suspected, investigators are required to notify the appropriate authorities. If a subject is believed to be a threat to herself / himself or others, the investigator should notify the appropriate authorities. The conditions under which the investigator may break confidentiality must be described here. As an example: All of the information you provide will be confidential. However, if we learn that you intend to harm yourself or others, we must report that to the authorities. For all studies in which links between subjects identities and data will be kept, add: Government staff or SWAGƵInstitutional Review Board members sometimes review studies such as this one to make sure they are being done safely and legally. If a review of this study takes place, you records may be examined. The reviewers will protect your identity. The study records will not be used to put you at legal risk of harm. For drug medical device studies regulated by the FDA, add: The U.S. Food and Drug Administration (FDA) reserves the right to review study data that may contain identifying information. For all applicable clinical trials, to include FDA-regulated drugs, biological products, and medical devices that will be registered with ClinicalTrials.gov and will post results in the federal data bank, a statement should be added to disclose this information: A description of this clinical trial will be available on  HYPERLINK "http://www.Clinical" http://www.Clinical Trials.gov, as required by the U.S. law. The web site will include a summary of the results. This web site will not include information that can identify you. You can search this web site at any time. If taping (video or audio) is to occur, the subjects must be informed. You must state how the tapes will be secured and stored, under whose supervision, who will score or transcribe, who will have access, and when they will be destroyed. For many studies, the following language may be appropriate: Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published but will not give your name or include any identifiable references to you. However, any records or data obtained as a result of your participation in this study may be inspected by the persons conducting this study and/or The Virginia College of Osteopathic Medicines Institutional Review Board, provided that such inspectors are legally obligated to protect any identifiable information from public disclosure, except where disclosure is otherwise required by law or a court of competent jurisdiction. These records will be kept private in so far as permitted by law. Compensation There is no requirement that subjects are compensated, but if they are, they must be fully informed. If no compensation is to be earned, subjects must be so informed. Money or redeemable coupons or other currency may be given. Subjects must be informed about how much will be paid, when it will be paid, any bonuses for completing all the tasks, etc. If extra credit in a course is the compensation, the subject must be informed as to how much credit is to be earned and the impact of that extra credit on their course grade. If extra credit is a form of compensation for participation in research involving human subjects, there must be alternate and equitable ways to earn the equivalent credit in the same course without participating as a subject in research (the subjects must be so informed). The course syllabus must describe the alternate ways to earn extra credit. Indicate what costs subjects may immediately or ultimately have to bear. If it is possible subjects may suffer a physical injury or illness as a result of taking part in the study state: If you think you have an injury or illness related to this study, contact the study staff right away. The study staff will treat you or refer you for treatment. State who will be responsible for the cost of such treatment. Freedom to Withdraw Subjects are free to withdraw from a study at any time without penalty. State that, if they choose to withdraw, they will be compensated for the portion of the time of the study (if financial compensation is involved). State that, if they choose to withdraw, they will not be penalized by reduction in points or grade in a course (if course credit is involved). Indicate that subjects are free not to answer any questions or respond to experimental situations that they choose without penalty. State that there may be circumstances under which the investigator may determine that a subject should not continue in the study and describe these circumstances. State that the subject will be compensated for the portion of the project completed (if financial compensation is involved). The following statement or a similar statement in language appropriate to the subjects could be used: You are free to choose whether or not to participate in this study. There will be no penalty if you choose not to participate. You will be provided with any significant new findings developed during the course of this study that may relate or influence your willingness to continue participation. In the event you decide to discontinue your participation in the study, please notify [name, telephone no., etc.] of your decision so that your participation can be terminated in an orderly fashion. Participants Responsibilities Include the following: My child has the following responsibilities: List medical conditions to be reported, staying in a place for a specific length of time after drawing a blood sample, consumption of alcohol etc. Parental Permission Statement Informed consent forms should include the following statement: I have read this form, and I give permission for my child to participate in the research study described above. I have had all of my questions answered. I understand that I will receive a copy of this form. I hereby acknowledge the above and give my parental permission. I understand that my permission does not take away any legal rights. I further understand that nothing in this consent form is intended to replace any applicable Federal, state, or local laws. If relevant, also include the following: I give permission to the researchers to use my medical records as described in this consent form. _______________________ Printed name of participating student ____________________________________________________ __________ Printed name of parent Signature of parent Date Should I have any pertinent questions about this research or its conduct, research subjects' rights, and whom to contact in the event of a research-related injury to the subject, I may contact: List Investigator(s) Phone & Email For questions I may have about this study. SWAGƵIRB Chairman P. Gunnar Brolinson, DO (540) 231-3041, pbrolins@vcom,vt.edu For questions I may have about my rights as a research subject. NOTE: Subjects must be given a complete copy (or duplicate original) of the signed Informed Consent.     SWAGƵIRB: Parent Permission Template Updated 8.17.17  +ABTWcefgh  ܴueuVG;euhCJOJQJaJh?h`Z~CJOJQJaJh?hCJOJQJaJhh5CJOJQJaJhh5CJOJQJaJhh+5CJOJQJaJhh`Z~5CJOJQJaJhh`Z~CJOJQJaJ.hh5;B*CJOJQJ\aJphh#5;CJOJQJ\aJ%hh`Z~5;CJOJQJ\aJhk&5;CJOJQJ\aJ+BTUVWh W X q W X Y { gdgd#gdgd p^p`gdgd`Z~$a$gd+ $xa$gd V W X p q   " E P S ^ _ V W X ¯yi\iI%hdh#6CJOJQJ\]aJh#6CJOJQJaJh(h#6CJOJQJaJ%h(h#6CJOJQJ\]aJ%h?h#6CJOJQJ\]aJh#6CJOJQJ\]aJ%h?h6CJOJQJ\]aJ hh+ hh"hh`Z~CJOJQJ\]aJh?hCJOJQJaJh?hCJOJQJaJX Y { STdef?@AF\]置؄tdtUQh-3hh-#CJOJQJaJhh-#5CJOJQJaJhh-Y5CJOJQJaJhh-YCJOJQJaJhhV2CJOJQJaJhV2CJOJQJaJhV2hV2CJOJQJaJhCJOJQJaJhh+CJOJQJaJhh`Z~CJOJQJaJ hh`Z~"hhCJOJQJ\]aJfg@A]#$|}^_   JgdgdQ gd-3gd`Z~gdV2]$|}]^ J ,-7`a56GH7ͺɳ||hHYCJOJQJaJh?h`Z~6CJOJQJaJhh+CJOJQJaJh7CJOJQJaJ hh`Z~hh`Z~CJOJQJaJhhCJOJQJaJhQ CJOJQJaJhhQ CJOJQJaJh-3CJOJQJaJ+J-`aH#$: ; ?#@#0$gdVgd?gdgd`Z~7U"#$'()*#9 ; v !ْuh[Oh /CJOJQJaJh /6CJOJQJaJhmPU6CJOJQJaJhVhV6CJOJQJaJhd16CJOJQJaJhmPUhmPU6CJOJQJaJhmPUhV6CJOJQJaJhhVCJOJQJaJhVCJOJQJaJh`Z~CJOJQJaJhmPUCJOJQJaJhFBCJOJQJaJhh-YCJOJQJaJ!'!<"="^"_"r"s""">#?#@#g##1$n$o$$ض蛌}n}_O="hd1h/k6CJOJQJ]aJhd1h-#6CJOJQJaJhh/kCJOJQJaJhh+CJOJQJaJhh`Z~CJOJQJaJhhVCJOJQJaJh /h /CJOJQJaJh<tCJOJQJaJBh,!h /0JCJOJQJaJehfHq rjh /CJOJQJUaJh /CJOJQJaJhjNCJOJQJaJ0$1$='>''(()**++,,,,,----..//11-#+ۯ1/帿ܴ$$%%&&;'<'='>'K'''''(0()_)b)))Q*q***ʻxl]QEh`Z~CJOJQJaJhHYCJOJQJaJhhHYCJOJQJaJh}CJOJQJaJhh#CJOJQJaJhh+CJOJQJaJhh`Z~CJOJQJaJ hh`Z~hh/kCJOJQJaJhd1h/kCJOJQJaJ"hd1h-#6CJOJQJ]aJ"hd1h/k6CJOJQJ]aJ"hd1hd16CJOJQJ]aJ*{+,`,a,u,,,,,3-S-T-c-----m.n.z...////)/-/e///////<0=0x0y0"1#111տտտտտհ}}}nh+n6CJOJQJ]aJ"h+nh+n6CJOJQJ]aJ"h+nh-#6CJOJQJ]aJh+nh-#CJOJQJaJhh-#CJOJQJaJhh+CJOJQJaJ hh`Z~hh`Z~CJOJQJaJh+nh+n6CJOJQJaJh+nCJOJQJaJ+111112&222R2S2222233E3F3G3H3e33333ԁr`Q?`Q"hNh}6CJOJQJ]aJh}6CJOJQJ]aJ"hNh{6CJOJQJ]aJhNh{CJOJQJaJhNhh`Z~CJOJQJaJhNhN6CJOJQJaJhNh`Z~6CJOJQJaJh}6CJOJQJaJhNCJOJQJaJ hh`Z~ hh}h}hh{CJOJQJaJ"h+nh-#6CJOJQJ]aJ122235555555555536d6e6f6g6)7,7B7W7 (gdNgdN gdNgd{gdHYgdNgd`Z~gdLt33333344E4X4Z4[4k4p4{4444455H5555555ܾܾܾܯܾͯܝ~n_P_hhn&CJOJQJaJhh`Z~CJOJQJaJhNhNCJOJQJ]aJ"hNhN6CJOJQJ]aJhNCJOJQJ]aJ"h}h{6CJOJQJ]aJhHY6CJOJQJ]aJhN6CJOJQJ]aJh}6CJOJQJ]aJ"hNh{6CJOJQJ]aJ"hNh}6CJOJQJ]aJ55555555"6(636C6D6L6T6X6Y6c6d6f6g6)7*7,717A7O7V7W7777777پپٲپٲپ墓儓rcWhk&CJOJQJaJhHh{CJOJQJaJ"hHh{6CJOJQJ]aJhh-YCJOJQJaJhh+CJOJQJaJhh`Z~6CJOJQJaJhn&CJOJQJaJhhNCJOJQJaJh`Z~CJOJQJaJhNCJOJQJaJhh`Z~CJOJQJaJh}CJOJQJaJ"W7777778888|8}888888888888888gd-#gd+gd`Z~gd{7777778888&8*8{8|8}8~88888888888888ĵ֦whYQMQMQMQMIMIMIMhk&h'jh'UhhKCJOJQJaJhhW[oCJOJQJaJ1hh`Z~56B*CJOJQJ\]aJph+hh`Z~6B*CJOJQJ]aJphhh`Z~CJOJQJaJhHh+CJOJQJaJ"hHh{6CJOJQJ]aJhh+CJOJQJaJhh-YCJOJQJaJhk&CJOJQJaJ88888888888hhKCJOJQJaJh'hk&h^hvFh^6CJaJhk&hk&6CJaJhk&6CJaJ 888888888gd`Z~ !`'$dNgdk&501F:p`Z~/ =!8"8#8$8% s2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH ^@^  Heading 1$ & Fxx@&5CJKH$OJQJ\aJDA D Default Paragraph FontRiR  Table Normal4 l4a (k (No List TU`T `Z~ Hyperlink*7>*S*Y(phfq r@4@4 vFHeader  !4 @4 vFFooter  !.)!. vF Page Number$1$ /kgoohl0HBH Wz Balloon TextCJOJQJ^JaJN/QN WzBalloon Text CharCJOJQJ^JaJB' aB OComment ReferenceCJaJ<r< O Comment TextCJaJ:: OComment Text Char@jqr@ OComment Subject5\F/F OComment Subject Char5\PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w< 0b IKMP X ]7!$*135788 "$%'()+,./J0$1W788!#&*-0<^r0X@ @H 0(  0(  B S  ?]*^*{{009*urn:schemas-microsoft-com:office:smarttagsplaceB*urn:schemas-microsoft-com:office:smarttagscountry-region }0000000000000&(HP!!}00000000000003333 ++SSuu))&*&*2*2***Y+Y+e+e+++E,X,p,z,{,{,--------f.f.//////00{0{0|0}0000000000000 ++SSuu))&*&*2*2***Y+Y+e+e+++E,X,p,z,{,{,--------f.f.//////00{0{0|0}0}00000000000000d7 ܘ ,vm| gbV.b#$1MDaIDHO h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h hh^h`o(hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h ^`o(hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h ``^``o(hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h^`CJOJQJaJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh   ^ `o(hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.1m| d7 V.b#DaID 2        <         F#Kn6~+GD\M;#Kn6^-aI a ^-UM #Kn6L '-5^-gVh*QU+GD+Ch*Q`+GD#'- `#Kn6$^-Z|#^- t#+GDv8$+GD{U%]5%+GD *#Kn6,'-'-FT-{U%x)N.+GDE/{U%01^-kA4^-#Kn6E7#Kn6i;8+GD u9h*Q~b:'-fX;^-&;+GDR<^-*c>#Kn6B"?+GD-8[?^-ZdA^-vNB+GD"B+GD7$Bh*Q+GDg{zF+GD^Gh*Q0H+GDJ#Kn6#vBK#Kn65K^-NM{U%N+GDh*QYzgR+GD65Vh*Q 1X'-$`\h*QL\'- ^{U%9n^-^n'- p'-4r#Kn6Ces#Kn6#t^-^wh*Qyu~#Kn6+GDNp^-FE"5}++nQ x 'VWz+!-#3#n&k&.:2 3D>561;?j?v2jʱ-,/°ڴt<txy`Z~fOV2K#IB4N7LtHY-3e /mSc sd1~7w:{ H^}00@GGGG0@UnknownG.[x Times New Roman5Symbol3. .Cx Arial7. [ @Verdana5. .[`)Tahoma;Wingdings?= .Cx Courier NewA$BCambria Math"1hCXGNXo:<A)X<A)X!88x4e0e0 2QHP ?42!xxϝ !OUTLINE FOR INFORMED CONSENT FORM W. Eryn PerryGeiger, Deborah$      Oh+'0 ( H T ` lx$OUTLINE FOR INFORMED CONSENT FORMW. Eryn PerryNormalGeiger, Deborah4Microsoft Office Word@@D*@a@<bE<A) ՜.+,D՜.+,P  hp  EVVCOMXe0 "OUTLINE FOR INFORMED CONSENT FORM Title 8@ _PID_HLINKSAd]http://www.clinical/  !"#$%&'()*+,-./013456789;<=>?@ABCDEFGHIJKLMNOPQRSTUVWYZ[\]^_abcdefgjRoot Entry F ElData 21Table::WordDocument7bSummaryInformation(XDocumentSummaryInformation8`CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q